CD4 and neoplasm: In line with these findings, in B16-OVA-derived tumors, FOXP3−CD4+ and FOXP3+CD25+CD4+ cells per gram of tumor tissue were reduced following BO-112 treatment (Additional file 8: Figure S7C).